United Therapeutics UTHR Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $1.33B+11.7% | $1.2B+21.4% | $984.8M+35.4% | $727.3M+52.9% | ||
| $85.6M+18.1% | $72.5M+36.3% | $53.2M+3.7% | $51.3M+2.8% | ||
| $147.7M+2.6% | $144M+268% | $39.1M-64.2% | $109.2M-21.2% | ||
| —— | -$64.1M+0.5% | -$64.4M— | —— | ||
| —— | —— | —— | —— | ||
| $52.6M+12.2% | $46.9M+245% | $13.6M— | —— | ||
| $97.9M— | —— | —— | $44.5M+456% | ||
| $80.9M+1,052% | -$8.5M— | —— | —— | ||
| —— | —— | —— | —— | ||
| $1.56B+17.6% | $1.33B+35.7% | $978M+21.9% | $802.5M+34.2% | ||
| $520.5M+111% | $246.5M+7.0% | $230.4M+66.0% | $138.8M+14.9% | ||
| $3.41B+107% | $1.65B-34.5% | $2.51B+47.2% | $1.71B-9.9% | ||
| $1.86B— | —— | $0— | $0— | ||
| —— | —— | -$761.7M+6.1% | -$811.5M-66.7% | ||
| $1B— | —— | $0— | $0— | ||
| —— | $400M+300% | $100M— | —— | ||
| $173.9M+14.0% | $152.5M+55.6% | $98M+10.9% | $88.4M+76.8% | ||
| $16.6M+36.1% | $12.2M-11.6% | $13.8M— | —— | ||
| -$1.25B+0.5% | -$1.25B-10,445% | -$11.9M-116% | $75.4M+68.3% | ||
| —— | $489.5M— | —— | $72M— | ||
| $13.5M-66.4% | $40.2M-28.2% | $56M+92.4% | $29.1M+79.6% | ||
| $313.3M-21.8% | $400.6M+20.5% | $332.5M+20.6% | $275.7M+79.8% | ||
| $19.7M-18.9% | $24.3M— | —— | -$52.5M+20.3% | ||
| —— | $28.5M+23.9% | $23M— | —— | ||
| $55M— | —— | —— | $1.5M— | ||
| $1.58B+3.1% | $1.54B-28.1% | $2.14B+109% | $1.02B-25.4% | ||
| $1.86B— | —— | $0— | —— | ||
| —— | —— | —— | —— | ||
| $116.3M— | —— | —— | $14.5M— | ||
| $313.3M-21.8% | $400.6M+20.5% | $332.5M+20.6% | $275.7M+79.8% | ||
| —— | —— | $0— | $0— | ||
| $1.04B-3.7% | $1.08B+44.5% | $747.6M+12.6% | $663.7M+39.0% | ||
| $1.04B-3.7% | $1.08B+44.5% | $747.6M+12.6% | $663.7M+39.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does United Therapeutics generate?
- United Therapeutics (UTHR) generated $1.6B in operating cash flow over the trailing twelve months.
- What is United Therapeutics's free cash flow?
- After $546.4M of capital expenditures, United Therapeutics's free cash flow was $1.0B over the trailing twelve months, down 9.9% year over year.
- Where does United Therapeutics's cash flow data come from?
- Every line is extracted from United Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
